Validating Innovative Biosensors for Rett Autonomic Symptom Tracking

Launched by RETT SYNDROME RESEARCH TRUST · Mar 28, 2024

Keywords

ClinConnect Summary

The VIBRANT study is a clinical trial designed to test new wearable devices that help track symptoms in individuals with Rett syndrome, a condition that affects brain development. The goal is to see how well these biosensors can measure important health indicators like heart rate, breathing, sleep patterns, oxygen levels, and movement over a period of up to 9 weeks. Participants will wear these devices at home and keep track of their symptoms, while also coming to a clinic for an overnight sleep study. This will help researchers understand how effective and user-friendly these biosensors are for families managing Rett syndrome.

To be eligible for the study, participants must have a diagnosis of Rett syndrome linked to a specific genetic change (called a MECP2 variant) and have access to WiFi. Some individuals who are already taking part in another clinical trial may also join this study. Participants can expect to wear the biosensors intermittently and report their experiences, helping to advance the understanding of Rett syndrome and the use of technology in monitoring health. This study is not yet recruiting, so interested families should stay tuned for updates.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • diagnosis of Rett syndrome with a causative MECP2 genetic variant
• • Access to WiFi
• Exclusion Criteria:
• • Inability of participant to sleep alone
• • prolonged absence from home
• • medication use that may impact heart rate